Changes of Macrophage Migration Inhibitory Factor During Orthotopic Liver Transplantation

Medical University of Vienna

Status: Unknown

Conditions: Evidence of Liver Transplantation

Study type: Observational

Funder types: Other

Identifiers

NCT02695979

1458/2014

Details and patient eligibility

About

Collecting blood, graft liver effluent and urine samples from patients undergoing orthotopic liver transplantation.

Full description

Aims are to measure Macrophage Migration Inhibitory Factor, Macrophage Migration Inhibitory Factor II and its' soluble receptor CD74 in serum, liver graft effluent and urine in and evaluate MIF's role in hepatic ischemia/reperfusion injury, postoperative graft function and kidney function.

Enrollment: 100 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• End stage liver disease, chronic liver failure, orthotopic liver transplantation

Exclusion criteria

• Combined transplantations (liver plus kidney or lung), age under 18 y, acute liver failure

Trial design

100 participants in 1 patient group

Patients undergoing OLT

Description:

Patients aged 18-70 with end-stage liver disease undergoing orthotopic liver transplantation (OLT).